Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate
Autore:
Pickar, JH; Yeh, IT; Wheeler, JE; Cunnane, MF; Speroff, L;
Indirizzi:
Wyeth Ayerst Res, Clin Res & Dev, Philadelphia, PA 19101 USA Wyeth Ayerst Res Philadelphia PA USA 19101 ev, Philadelphia, PA 19101 USA Univ Texas, Hlth Sci Ctr, Dept Pathol, San Antonio, TX 78284 USA Univ Texas San Antonio TX USA 78284 ept Pathol, San Antonio, TX 78284 USA Univ Penn, Med Ctr, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA UnivPenn Philadelphia PA USA 19104 & Lab Med, Philadelphia, PA 19104 USA New Jersey Med Coll, Dept Anat Pathol & Cell Biol, Philadelphia, PA USA New Jersey Med Coll Philadelphia PA USA Cell Biol, Philadelphia, PA USA Oregon Hlth Sci Univ, Dept Obstet & Gynecol, Portland, OR 97201 USA OregonHlth Sci Univ Portland OR USA 97201 ynecol, Portland, OR 97201 USA
Titolo Testata:
FERTILITY AND STERILITY
fascicolo: 1, volume: 76, anno: 2001,
pagine: 25 - 31
SICI:
0015-0282(200107)76:1<25:EEOLDO>2.0.ZU;2-D
Fonte:
ISI
Lingua:
ENG
Soggetto:
HORMONE REPLACEMENT THERAPY; LUTEAL-PHASE DEFECTS; POSTMENOPAUSAL WOMEN; LONG-TERM; CANCER; HYPERPLASIA; RISK; DIAGNOSIS; REPRODUCIBILITY; VARIABILITY;
Keywords:
conjugated equine estrogens (CEE); medroxyprogesterone acetate (MPA); endometrial hyperplasia; postmenopausal women; menopause; hormone replacement therapy (HRT); lower HRT doses; Women's HOPE Study;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
28
Recensione:
Indirizzi per estratti:
Indirizzo: Pickar, JH Wyeth Ayerst Res, Clin Res & Dev, POB 42528, Philadelphia, PA 19101 USA Wyeth Ayerst Res POB 42528 Philadelphia PA USA 19101 19101 USA
Citazione:
J.H. Pickar et al., "Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate", FERT STERIL, 76(1), 2001, pp. 25-31

Abstract

Objective: To determine the endometrial safety of lower doses of continuous combined conjugated equine estrogens (CEE) and medroxyprogesterone acetate (MPA). Design: Randomized, double-blind, placebo-controlled study (the Women's Health, Osteoporosis, Progestin, Estrogen study). Setting: Study centers across the United States. Patient(s): Healthy, postmenopausal women (n = 2,673) with an intact uterus. Intervention(s): Patients received CEE 0.625 mg/day, CEE 0.625/MPA 2.5 mg/day, CEE 0.45 mg/day, CEE 0.45/MPA 2.5 mg/day, CEE 0.45/MPA 1.5 mg/day, CEE0.3 mg/day, CEE 0.3/MPA 1.5 mg/day, or placebo for 1 year. Endometrial biopsies were evaluated at baseline, cycle 6, and year 1 using a centralized protocol. Main Outcome Measure(s): Efficacy of lower doses of CEE/MPA in reducing the incidence of endometrial hyperplasia rates associated with unopposed CEE. Result(s): Endometrial hyperplasia rates ranged from 0 to 0.37% for all CEE/MPA doses. Twenty-nine of the 32 cases of endometrial hyperplasia developed in women who were administered CEE 0.625 mg or CEE 0.45 mg. The incidence of endometrial hyperplasia increased with age for patients administered CEE alone. As expected, there were some inconsistencies among pathologists' ratings in the numbers of hyperplasias and incidence rates for the CEE-alone regimens. There were too few cases of hyperplasia in the combination groups to evaluate consistency among pathologists. Conclusion(s): One year of treatment with lower doses of CEE/MPA provides endometrial protection comparable to commonly prescribed doses. These regimens may be used by clinicians to individualize hormone replacement therapy in postmenopausal women. (C) 2001 by American So'iety for Reproductive Medicine.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 19/01/20 alle ore 20:25:44